guest ::
| Home > Publications database > IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma. > print |
| Home > Publications database > IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma. > print |
| 001 | 308662 | ||
| 005 | 20260126120550.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ccell.2025.12.020 |2 doi |
| 024 | 7 | _ | |a pmid:41576930 |2 pmid |
| 024 | 7 | _ | |a 1535-6108 |2 ISSN |
| 024 | 7 | _ | |a 1878-3686 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2026-00195 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Collot, Raphaël |b 0 |
| 245 | _ | _ | |a IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma. |
| 260 | _ | _ | |a Cambridge, Mass. |c 2026 |b Cell Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1769422529_3983886 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub |
| 520 | _ | _ | |a Diffuse midline glioma (DMG) is an aggressive pediatric brain tumor with no curative treatment, and lacks a comprehensive understanding of immune-tumor cell interactions within their spatial context. Our multi-omics approach, integrating single-nuclei RNA sequencing, spatial transcriptomics, and high-dimensional imaging, utilizes patient samples and an experimental murine DMG model to unveil two spatially distinct regions. MES-patterns are defined by mesenchymal (MES) tumor cells and blood-derived immune cells, whereas AOO-patterns are enriched with astrocyte (AC)-, oligodendrocyte (OC)-, and oligodendrocyte precursor cell (OPC)-like cancer populations, alongside homeostatic-like microglia. The less-studied immune checkpoint, IGSF11, is primarily expressed by AOO-associated cancer cells, while its receptor VISTA is detected mainly in homeostatic microglia. Targeting IGSF11-VISTA results in tumor reduction and survival benefit, mediated by brain-resident microglia and independent of T cell infiltration. This positions IGSF11-VISTA as a promising immune checkpoint treatment axis to harness the local brain immune response against DMG. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a IGSF11-VISTA immune checkpoint |2 Other |
| 650 | _ | 7 | |a cancer-immune landscape |2 Other |
| 650 | _ | 7 | |a diffuse midline glioma |2 Other |
| 650 | _ | 7 | |a microglia-cancer interaction |2 Other |
| 650 | _ | 7 | |a spatial multi-omics profiling |2 Other |
| 700 | 1 | _ | |a Ruiz-Moreno, Cristian |b 1 |
| 700 | 1 | _ | |a Honhoff, Celina |b 2 |
| 700 | 1 | _ | |a van den Broek, Thijs J M |b 3 |
| 700 | 1 | _ | |a Wezenaar, Amber K L |b 4 |
| 700 | 1 | _ | |a Kloosterman, Daan J |b 5 |
| 700 | 1 | _ | |a Ariese, Hendrikus C R |b 6 |
| 700 | 1 | _ | |a Johnson, Hannah |b 7 |
| 700 | 1 | _ | |a Vervoort, Britt M T |b 8 |
| 700 | 1 | _ | |a Jeiroshi, Amal |b 9 |
| 700 | 1 | _ | |a Bunt, Jens |b 10 |
| 700 | 1 | _ | |a van Ineveld, Ravian L |b 11 |
| 700 | 1 | _ | |a Bokobza, Emma |b 12 |
| 700 | 1 | _ | |a Rebel, Heggert G |b 13 |
| 700 | 1 | _ | |a Te Pas, Brigit M |b 14 |
| 700 | 1 | _ | |a Ringnalda, Femke C A |b 15 |
| 700 | 1 | _ | |a van de Wetering, Marc |b 16 |
| 700 | 1 | _ | |a Robe, Pierre A |b 17 |
| 700 | 1 | _ | |a Kool, Marcel |0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |b 18 |u dkfz |
| 700 | 1 | _ | |a Cochran, Jennifer R |b 19 |
| 700 | 1 | _ | |a Kranendonk, Mariëtte E G |b 20 |
| 700 | 1 | _ | |a van Vuurden, Dannis G |b 21 |
| 700 | 1 | _ | |a Hulleman, Esther |b 22 |
| 700 | 1 | _ | |a Wehrens, Ellen J |b 23 |
| 700 | 1 | _ | |a Zomer, Anoek |b 24 |
| 700 | 1 | _ | |a Stunnenberg, Hendrik G |b 25 |
| 700 | 1 | _ | |a Rios, Anne C |b 26 |
| 773 | _ | _ | |a 10.1016/j.ccell.2025.12.020 |g p. S1535610825005549 |0 PERI:(DE-600)2074034-7 |p nn |t Cancer cell |v nn |y 2026 |x 1535-6108 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:308662 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2026 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-20 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-20 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER CELL : 2022 |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-20 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-20 |
| 915 | _ | _ | |a IF >= 50 |0 StatID:(DE-HGF)9950 |2 StatID |b CANCER CELL : 2022 |d 2024-12-20 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|